Healthians Founder Sahni Launches New Venture ‘Un:bloc’

Why It Matters

Un:Bloc signals a new wave of ambitious, purpose‑driven health‑tech disruption in India, potentially reshaping how systemic healthcare issues are addressed. Sahni’s track record and fresh capital injection could accelerate innovation across the sector.

Key Takeaways

• Healthians reached ~₹3,000 crore ($360 M) valuation under Sahni.
• Sahni announced new venture Un:Bloc on World Health Day.
• Un:Bloc aims to tackle systemic health challenges at scale.
• Sahni pledged ₹100 crore ($12 M) to early‑stage startups.
• Details remain secret, hinting at a potentially disruptive health‑tech platform.

Pulse Analysis

Healthians, founded in 2015, transformed India’s diagnostic landscape by offering doorstep testing in more than 250 cities. Under Deepak Sahni’s stewardship, the company scaled to a valuation of roughly ₹3,000 crore (approximately $360 million), positioning it among the country’s most valuable health‑tech firms. Sahni’s exit from the executive role and his reputation as a serial entrepreneur set the stage for his next move, which he announced on World Health Day—a symbolic date that underscores a commitment to public health.

The newly minted venture, Un:Bloc, is deliberately shrouded in secrecy, but its branding hints at a mission to “unblock” entrenched systemic barriers in healthcare. Analysts speculate that the startup could target areas such as integrated health data platforms, affordable preventive care, or AI‑driven diagnostics, leveraging Sahni’s deep industry connections. By framing the initiative around large‑scale disruption, Un:Bloc aims to attract both strategic partners and venture capital eager to back transformative solutions in a market projected to exceed $150 billion by 2030.

Sahni’s concurrent pledge of ₹100 crore ($12 million) to early‑stage startups over three years reinforces his role as a catalyst for ecosystem growth. This commitment not only fuels nascent health‑tech ideas but also signals confidence in India’s innovation pipeline. For investors and competitors alike, Un:Bloc represents a bellwether for the next phase of health‑tech evolution—one that blends ambitious scale with purpose‑driven impact, potentially reshaping policy, delivery models, and patient outcomes across the subcontinent.